|
OPEN ACCESS PLUS
Accepted articles are published online for free open access for all to view. Open access publishing provides the maximum dissemination of the article to the largest audience. Authors must pay for this service. All corresponding authors will be asked to indicate whether or not they wish to pay to have their paper made freely available on publication. If authors do not select the Open Access option, then their article will be published with standard subscription-based access at no charge.
Authors who opt for Open Access Plus may also self-archive publishers postprints. Bentham Science is compliant with the open access policy for the MRC, Cancer Research UK, NIH, and many other funders. For details, refer to http://www.benthamscience.com/permission.php or email to; openaccess@benthamscience.org.
Contents
7(1): Pp. 2 - 8
Sergio O. Angel, Mariana Matrajt and Pablo C. Echeverria
[Open Access Plus] |
|
Diseases caused by protozoan parasites are still an important health problem. These parasites can cause a wide spectrum of diseases, some of which are severe and have high morbidity or mortality if untreated. Since they are still uncontrolled, it is important to find novel drug targets and develop new therapies to decrease their remarkable social and economic impact on human societies. In the past years, human HSP90 has become an interesting drug target that has led to a large number of investigations both at state organizations and pharmaceutical companies, followed by clinical trials. The finding that HSP90 has important biological roles in some protozoan parasites like Plasmodium spp, Toxoplasma gondii and trypanosomatids has allowed the expansion of the results obtained in human cancer to these infections. This review summarizes the latest important findings showing protozoan HSP90 as a drug target and presents three patents targeting T. gondii, P. falciparum and trypanosomatids HSP90.
|
6(3): Pp. 212 - 222
Andrea M.P. Romani
[Open Access Plus] |
|
Magnesium (Mg2+) is used pharmacologically to sedate specific forms of arrhythmias. Administration of pharmacological doses of catecholamine or adrenergic receptor agonists often results in arrhythmias onset. Results from the present study indicate that stimulation of cardiac adrenergic receptors elicits an extrusion of cellular Mg2+ into the extracellular space. This effect occurs in both perfused hearts and isolated cells within 5-6 min following either β- or α1- adrenergic receptor stimulation, and is prevented by specific adrenergic receptors antagonists. Sequential stimulation of the two classes of adrenergic receptor results in a larger mobilization of cellular Mg2+ provided that the two agonists are administered together or within 1-2 min from each other. A longer delay in administering the second stimulus results in the abolishment of Mg2+ extrusion. Hence, these data suggest that the stimulation of β- and α1-adrenergic receptors mobilizes Mg2+ from two distinct cellular pools, and that Mg2+ loss from either pool triggers a Mg2+ redistribution within the cardiac myocyte. At the sarcolemmal level, Mg2+ extrusion occurs through a Na+/Mg2+ exchange mechanism phosphorylated by cAMP. Administration of quinidine, a patent anti-arrhythmic agent, blocks Na+ transport in a non-specific manner and prevents Mg2+ extrusion. Taken together, these data indicate that catecholamine administration induces dynamic changes in total and compartmentalized Mg2+ pools within the cardiac myocytes, and suggest that prevention of Mg2+ extrusion and redistribution may be an integral component of the effectiveness of quinidine and possibly other cardiac antiarrhythmic agents. Confirmation of this possibility by future experimental and clinical studies might result in new patents of these compounds as Mg2+ preserving agents.
|
|
